Clinical Trial Update: ONC201 in Adults With Recurrent H3 K27M-mutant Glioma [Phase 2]

View source ↗

Summary

Jazz Pharmaceuticals’ ONC201 phase 2 trial in adults with recurrent H3 K27M-mutant diffuse midline glioma has been terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Midline Glioma H3 K27-altered

Drugs mentioned

• ONC201 (ONC201)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Glioma | Phase 2 | Status: TERMINATED | Results posted: 2025-07-28